Curr Opin Pulm Med. 2019 Mar;25(2):158-164. doi: 10.1097/MCP.0000000000000555.

Procalcitonin and other markers to guide antibiotic use in chronic obstructive pulmonary disease exacerbations in the era of antimicrobial resistance.

Wang J(1), Cao B(2).

Author information:

(1)Department of Pulmonary and Critical Care Medicine, Beijing Luhe Hospital, Capital Medical University.

(2)Department of Pulmonary and Critical Care Medicine, Center for Respiratory Diseases, China-Japan Friendship Hospital National Clinical Research Center of Respiratory Diseases Capital Medical University.

PURPOSE OF REVIEW: This review summarizes the latest discoveries regarding the use of clinical indicators and biomarkers to guide antibiotic use in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD), and it analyzes the advantages and disadvantages of various indicators and markers. RECENT FINDINGS: For AECOPD patients admitted to emergency departments and medical wards, procalcitonin (PCT)-guided antibiotic therapy reduced antibiotic use without adverse outcomes. In contrast, for severe AECOPD patients admitted to ICUs, PCT-guided antibiotic therapy increased the overall mortality in a 3-month follow-up period, and antibiotic use was not decreased. SUMMARY: PCT is the most promising biomarker to guide antibiotic use in patients with AECOPD. However, patients with severe AECOPD admitted in ICU may not benefit from PCT-guided antibiotic therapy.

DOI: 10.1097/MCP.0000000000000555 PMID: 30550505